Aytu Stock Jumps 46% After Rosemont's $2.70 Cash Tender Offer
Aytu shares rose most of the way to Rosemont's $2.70 offer in Monday's after-hours session and have traded just below it since. The deal needs a majority of shares tendered, and closing is anticipated in late December.

Aytu BioPharma, Inc. (NASDAQ: AYTU) agreed to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, according to a merger filing made at 4:03 p.m. ET on Monday, Nov. 16, in after-hours trading. Nasdaq had halted the stock three minutes earlier. The price is a 51.7% premium to the Nov. 13 close, according to the release.
Shares sit just below the offer price
Most of the 46% gain came in Monday's after-hours session, after the halt and the offer filing. In Tuesday's regular session the stock traded between $2.65 and $2.67, under the $2.70 offer. Aytu's first-quarter results came out the same evening, so the offer and the earnings arrived together.
Shares jumped 44% after the halt, then barely moved
Nasdaq halted trading at 4:00:10 p.m. ET Monday, with news pending, and resumed it at 4:40 p.m. In after-hours trading (the session after the 4 p.m. close), the stock rose 43.96% to $2.62. Before the halt, Aytu had gained 2.25% in Monday's regular session to close at $1.82. The cause of that gain is not clear.
On Tuesday, pre-market trading (before the 9:30 a.m. open) reached $2.67 on about 1.00 million shares, 1.9% above the after-hours close. The regular session closed at $2.66, up 46.15% from Monday's close, on 3.24 million shares. That was 0.36% below the pre-market close. As of 4:55 p.m., after-hours trading on Tuesday had the stock at $2.65 on 168,808 shares.
Before the news the stock had drifted lower. From Oct. 19 to Nov. 16 it fell 7.14%, with a high of $2.12 on Oct. 21 and a low of $1.75 on Nov. 5.
A thin float and a $56 million deal
Aytu's float (shares available to trade) is about 9.97 million, and Tuesday's regular-session volume was about a third of it. The 10-day average volume is about 172,699 shares a day, so Tuesday's trading ran far above normal.
The company said the deal is valued at about $56 million on a fully diluted basis, which counts warrants and other securities that could become shares. The $2.70 price is also a 41.1% premium to the 30-day volume-weighted average price, an average that weights each price by the shares traded at it.
Board approval, support agreements and a quarter of growth
Aytu said its board approved the deal unanimously. Stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management, along with Aytu's directors and officers, signed agreements to tender their shares. Chief Executive Josh Disbrow said the deal delivers "compelling value to our shareholders."
The first-quarter report, for the period ended Sept. 30, showed:
- Net revenue of $14.8 million, up 6.9% from $13.9 million a year earlier.
- EXXUA, its antidepressant, brought in $4.9 million, up 24.5% from the prior quarter.
- Total prescriptions rose 32.5% from the prior quarter to 4,400.
- A net loss of $3.9 million, against net income of $2.0 million in the year-earlier quarter.
Analysts had expected a loss of about 26 cents per share, and Aytu reported a loss of 20 cents. Revenue estimates varied. Aytu said it would not hold an earnings call because of the pending merger.
Rosemont, based in Leeds, U.K., makes oral liquid medicines. Its CEO, Alok Sonig, called the deal a step in the company's U.S. growth strategy.
What comes next
- Rosemont plans to launch the tender offer and submit its Schedule TO within 10 business days. Aytu will file a Schedule 14D-9, with more detail on the process behind the deal, at about the same time.
- The tender offer requires shares representing a majority of Aytu's outstanding stock, plus the exercise or termination of certain warrants.
- Closing is anticipated in late December 2026, subject to the offer's conditions. A second-step merger would then buy any untendered shares at the same price, except those whose holders properly exercise appraisal rights.
Bottom line
Aytu's 46% jump follows a cash offer at a 51.7% premium to the Nov. 13 close, and the shares trade just under $2.70. The quarter brought higher revenue and EXXUA sales along with a net loss. Completion depends on the tender offer's conditions and the late-December timetable.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




